Chester County News and Community Website
PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) is targeting a second-half 2027 Biologics License Application for rese-cel in myositis while preparing another registrational study in systemic sclerosis, advancing its …
Cabaletta Targets 2027 BLA as Cell Therapy Trials Advance Read More PHILADELPHIA, PA — Cabaletta Bio (Nasdaq: CABA) reported new clinical data suggesting its lead CAR-T cell therapy candidate could support regulatory filings in multiple autoimmune diseases, prompting the company to …
Cabaletta Expands Autoimmune Strategy on Mid-Stage Data Read More PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) reported first-quarter financial results and outlined plans to advance its autoimmune disease cell therapy program toward potential regulatory filings, while expanding manufacturing …
Cabaletta Advances Pivotal Trials as Cash Runway Extends Read More PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) reported early clinical data showing two of four autoimmune disease patients treated with its experimental CAR-T therapy remained drug-free for six months …
Cabaletta Reports Drug-Free Responses in CAR-T Study Read More PHILADELPHIA, PA & SOUTH SAN FRANCISCO, CA — Cabaletta Bio, Inc. (Nasdaq: CABA) and Cellares have entered a commercial agreement to manufacture rese-cel, an investigational cell therapy for autoimmune diseases, …
Cabaletta, Cellares Sign Manufacturing Deal for Rese-Cel Supply Read More PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) will present clinical, translational and manufacturing data on its investigational CAR T therapy rese-cel at the American Society of Gene & Cell …
Cabaletta Bio to Present Rese-Cel Data at ASGCT 2026 Meeting Read More PHILADELPHIA, PA — Cabaletta Bio Inc. (Nasdaq: CABA) recently reported fourth-quarter and full-year 2025 results and said it is advancing clinical development of its rese-cel cell therapy program for autoimmune …
Cabaletta Reports Results, Advances Rese-Cel Autoimmune Program Read More PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) said it will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026, placing fresh attention on the Philadelphia-based …
Cabaletta Bio Takes Spotlight at Guggenheim Summit as Autoimmune Bet Advances Read More PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) laid out an ambitious 2026 roadmap centered on advancing rese-cel, its experimental CAR T cell therapy for autoimmune diseases, as the company …
Cabaletta Targets 2027 FDA Filing as Autoimmune CAR-T Push Accelerates Read More PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) reported third-quarter results and outlined major clinical and regulatory milestones that position its lead therapy, rese-cel, as a potential first-in-class CAR T …
Cabaletta Bio’s Bold Autoimmune Push Raises Big Questions About the Future of CAR T Read More